CD14 and melanoma: For instance, Jordan et al. demonstrated that the frequency of both M-MDSCs (Lin−CD11b+HLA-DR−/lowCD33+CD14+) and G-MDSCs (Lin−CD11b+HLA-DR−/lowCD33+CD14−) subsets was significantly increased in the peripheral blood of stage IV melanoma patients and was associated with disease progression and decreased OS (142).